The drug is "Aklasta". Instructions

The drug "Aklasta", analogues of the drug ("Veroclast", "Blaztera", "Zolendronate-Teva" and others) can slow down the destruction of bone tissue. Zelendronic acid - the active ingredient - is included in the class of bisphosphonates (synthetic substances that prevent the loss of bone mass).

The drug is "Aklasta". Description

The drug is released in the form of a solution for infusion.

After intravenous administration, the active ingredient is distributed rapidly into the bone tissue. Like other bisphosphonates, the greadronic acid is localized mainly in the areas of resorption (destruction).

Preventing destruction, the active component does not adversely affect the mechanical properties, the process of formation and mineralization of the bone.

The drug is "Aklasta". Instruction: indications

Medication is prescribed for Paget's bone disease (deforming osteitis), postmenopausal osteoporosis (to reduce the probability of fractures in the spine, femoral and other bones and increase their mineral density), to prevent fractures after bone injuries in the hip joint.

Means of "Aklast." Instruction: Dosage regimen

Before the introduction of the drug it is necessary to ensure optimal hydration (water saturation) of the body. This is especially important when using diuretic therapy.

For the prevention of fractures after hip joint injuries and the treatment of osteoporosis of the postmenopausal drug "Aklasta", the instruction recommends injecting intravenous infusion once a year in an amount of five milligrams (one time). Against therapy, concomitantly take calcium and vitamin D.

In the treatment of Paget's disease, the intravenous administration of the drug "Aklasta" recommends the use of a dose of five milligrams in a hundred milliliters of an aqueous solution administered intravenously with a separate infusion system. The injection time is not less than fifteen minutes, the speed must be constant. Due to the fact that Paget's disease is characterized by progressive destruction of the bone, an additional daily rate of vitamin D and calcium is recommended for all patients with this pathology during the first ten days after the infusion.

The first injection of the drug "Aklasta" causes a prolonged period of remission of the deforming osteitis. For today, there is no specific information on the re-therapy of Paget's disease. However, such treatment is possible if the patient has a relapse. Secondary development of pathology is characterized by the following symptoms: the lack of normalization of serum alkaline phosphatase , an increase in its level of dynamics, and the presence of clinical symptoms of Paget's disease, revealed after twelve months after the application of the dose of the drug "Aklasta".

The drug is not recommended for patients with severe renal impairment.

Elderly and patients with disorders of liver function correction dosage is not required.

Due to the lack of data on the safety and effectiveness of the use of the drug "Aklast" in patients under the age of eighteen, they are not prescribed a drug.

After the introduction of the drug, the development of fever, flu-like syndrome, increased fatigue, the appearance of swelling (rarely), malaise, asthenia, chills. Frequent adverse reactions are headaches, lethargy, dizziness, dyspnea. Sometimes there may be paresthesia, fainting, tremor, drowsiness. Patients may feel pain in the spine, bones. Perhaps the development of myalgia, arthralgia, dyspepsia, vomiting, nausea and other side effects.

Contraindicated drug in lactation, hypocalcemia, pregnancy, hypersensitivity.